A new era of unapproved drugs: The case of Abigail Alliance v Von Eschenbach

JAMA

Volumn 297, Issue 2, 2007, Pages 205-208

  Jacobson, Peter D ^a   Parmet, Wendy E ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONIFIDE; ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ROFECOXIB; UNCLASSIFIED DRUG;

ALLERGIC REACTION; BLOOD TOXICITY; BREAST CANCER; CHROMOSOME ANALYSIS; CLINICAL TRIAL; COLON CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LEUKOPENIA; NOTE; PHYSICIAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TUMOR;

EID: 33846141187     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.2.205     Document Type: Note

References (21)

1. Pure Food and Drug Act, Pub L No. 59-384, 34 Stat 768 (1906).
2. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press; 2006.
3. Pilon R. Rule of law: whose life is it, anyway? Wall Street Journal. June 3, 2006:9.
4. Abigail Alliance for Better Access to Developmental Drugs v Von Eschenbach, 445 F3d 470 (DC Cir 2006), vacated 2006 US App LEXIS 28974 (DC Cir November 21, 2006).
5. 2006 US App LEXIS 28974 (DC Cir November 21, 2006).
6. Mayer M. Listen to all the voices: an advocate's perspective on early access to investigational therapies. Clin Trials. 2006;3:149-153.
7. The Abigail Alliance. The Abigail story. http://abigail-alliance.org/ story.htm. Accessed August 7, 2006.
8. 21 CFR 312.34 et seq.
9. Citizen petition of the Abigail Alliance and the Washington Legal Foundation. http://www.abigail-alliance.org/WLF_FDA.pdf. Accessed September 4, 2006.
10. Experimental drugs for the terminally ill. Capitol Hill Hearing Testimony. http://abigail-alliance.org/testimony.htm. Accessed November 18, 2006.
11. US Food and Drug Administration. FDA proposes rules overhaul to expand availability of experimental drugs. http://www.fda.gov/bbs/topics/NEWS/2006/ NEW01520.html. Accessibility verified December 18, 2006.
12. Washington v Glucksberg, 521 US 702 (1997).
13. Cruzan v Director, Missouri Department of Health, 497 US 261 (1990).
14. United States v Rutherford, 442 US 544 (1979).
15. United States v Raich, 545 US 1 (2005).
16. Costanza ME, Berry D, Henderson IC, et al. Amonifide: an active agent in the treatment of a previously untreated advanced breast cancer - a Cancer and Leukemia Group B study (CALGB 8642). Clin Cancer Res. 1995;1:699-704.
17. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711-716.
18. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69:297-307.
19. Kianna's law. The Wall Street Journal. November 15, 2005:A22.
20. Initial brief for appellant-petitioner, Abigail Alliance for Better Access to Developmental Drugs v Crawford, 2004 US DC Cir 5350, 2005 US DC Cir LEXIS 89 (June 30, 2005).
21. ACCESS Act (Access, Compassion, Care, and Ethics for Seriously Ill Patients), S 1956, 109th Cong (2005).